Since 1990, Lung Foundation Australia has invested 40.9 million into funding the ground-breaking projects of over 270 Australian researchers. We have also funded 31 clinical trials to advance treatments and care in lung cancer and Pulmonary Fibrosis.
In recent years, advancements in treatments have seen an increase in survival rates and quality of life across several lung conditions – providing hope that has never existed before.
In the last 20 years lung cancer mortality rates have decreased more than any other cancer.
Since 2017, anti-fibrotic medications listed on the Pharmaceutical Benefits Scheme have greatly slowed the progression of lung function deterioration in people living with Interstitial Lung Disease.
This is only made possible by the generous support from our passionate community – together we have made an undeniable impact on the future of lung disease and lung cancer. Now more than ever, we need to work together and build on the momentum created to drive real and lasting change.